Olaparib (AZD2281, Ku-0059436)

Catalog No.S1060

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

Cited by 92 Publications

Nature, 2018, 555(7696):387-391

PubMed: 29513652 ( click the link to review the publication )

Nature, 2018, 560(7716):112-116

PubMed: 30022158 ( click the link to review the publication )

Nature, 2018, 560(7716):117-121

PubMed: 30022168 ( click the link to review the publication )

Nature, 2017, 549(7673):548-552

PubMed: 28959974 ( click the link to review the publication )

Nature, 2017, 550(7676):360-365

PubMed: 28976962 ( click the link to review the publication )

Nature, 2015, 528(7582):422-6

PubMed: 26649820 ( click the link to review the publication )

Science, 2013, 339(6120):700-4

PubMed: 23306437 ( click the link to review the publication )

Cell, 2018, 173(4):972-988

PubMed: 29656893 ( click the link to review the publication )

Cell, 2017, S0092-8674(17)31437-X

PubMed: 29290468 ( click the link to review the publication )

Cell, 2011, 145(4):529-42

PubMed: 21565612 ( click the link to review the publication )

Nat Methods , 2013, 10(10):981-4

PubMed: 23955771 ( click the link to review the publication )

Cancer Discov, 2012, 2(11):1036-47

PubMed: 22915752 ( click the link to review the publication )
Cell Metab, 2014, 19(6):1034-41

PubMed: 24814482 ( click the link to review the publication )

Blood, 2017, 130(26):2848-2859

PubMed: 29042365 ( click the link to review the publication )

Blood, 2016, 127(1):139-48

PubMed: 26463424 ( click the link to review the publication )

Hepatology, 2012, 55(6):1840-51

PubMed: 22223166 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(9):837-840

PubMed: 30013063 ( click the link to review the publication )

ACS Nano, 2011, 5(11):9216-24

PubMed: 21962084 ( click the link to review the publication )

Nat Struct Mol Biol, 2012, 19(4):417-23

PubMed: 22388737 ( click the link to review the publication )

Nat Protoc, 2017, 12(9):1951-1961

PubMed: 28837130 ( click the link to review the publication )

Nat Commun, 2014, 5:3361

PubMed: 24553445 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(11):7028-38

PubMed: 24861619 ( click the link to review the publication )

J Thorac Oncol, 2017, 12(8):1309-1319

PubMed: 28389374 ( click the link to review the publication )

EMBO Mol Med, 2012, 4(10):1087-96

PubMed: 22933245 ( click the link to review the publication )
Clin Cancer Res, 2013, 19(18):5003-15

PubMed: 23881923 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 12(7):529-34

PubMed: 23684799 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-1673

PubMed: 30733193 ( click the link to review the publication )

Cancer Res, 2014, 74(21):5948-54

PubMed: 25145669 ( click the link to review the publication )

Cancer Res, 2013, 72(11):2814-21

PubMed: 22447567 ( click the link to review the publication )

Cancer Res, 2013, 74(1):287-97

PubMed: 24240700 ( click the link to review the publication )

EMBO Rep, 2010, 11(12):962-8

PubMed: 21052091 ( click the link to review the publication )

Cell Rep, 2014, 8(6):1808-18

PubMed: 25199834 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.29747

PubMed: 29313488 ( click the link to review the publication )

Int J Cancer, 2019, 144(5):1092-1103

PubMed: 30152517 ( click the link to review the publication )

Nanoscale, 2015, 7(6):2805-11

PubMed: 25584654 ( click the link to review the publication )

Eur J Cancer, 2014, 50(15):2725-34

PubMed: 25128455 ( click the link to review the publication )
Oncogene, 2015, 10.1038/onc.2015.212

PubMed: 26073085 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.443

PubMed: 25619829 ( click the link to review the publication )

Oncogene, 2013, 32(47):5377-87

PubMed: 23934192 ( click the link to review the publication )

Oncogene, 2012, 32(39):4634-45

PubMed: 23108394 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):20-8

PubMed: 24534203 ( click the link to review the publication )

Cancer Lett, 2013, 343(2):217-23

PubMed: 24215868 ( click the link to review the publication )

Cancer Lett, 2012, 319(2):232-41

PubMed: 22266096 ( click the link to review the publication )

Sci Signal, 2014, 7(326):ra47

PubMed: 24847116 ( click the link to review the publication )

J Med Chem, 2014, 57(13):5579-601

PubMed: 24922587 ( click the link to review the publication )

J Med Chem, 2012, 55(7):3011-20

PubMed: 22380680 ( click the link to review the publication )

J Exp Clin Cancer Res, 2013, 32(1):95

PubMed: 24252502 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(2):R25

PubMed: 24625110 ( click the link to review the publication )
J Cereb Blood Flow Metab, 2014, 127(23):5079-92

PubMed: 25248836 ( click the link to review the publication )

J Neuroscience, 2014, 34(28):9338-50

PubMed: 25009267 ( click the link to review the publication )

Arch Toxicol, 2014, 10.1007/s00204-014-1434-0

PubMed: 25526924 ( click the link to review the publication )

Bioinformatics, 2016, 32(12):i253-i261

PubMed: 27307624 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-16-0740

PubMed: 28500233 ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-14-0810

PubMed: 25777962 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(5):1236-46

PubMed: 25777962 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(6):1645-54

PubMed: 24694947 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(3):724-32

PubMed: 24356817 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(6):1645-54

PubMed: 24694947 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):986-95

PubMed: 24552776 ( click the link to review the publication )

Mol Oncol, 2014, 10.1016/j.molonc.2014.07.022

PubMed: 25139258 ( click the link to review the publication )
Mol Oncol, 2014, S1574-7891(14)00132-X

PubMed: 25028150 ( click the link to review the publication )

Carcinogenesis, 2013, 34(4):739-49

PubMed: 23275151 ( click the link to review the publication )

Neoplasia, 2012, 14(3):169-77

PubMed: 22496617 ( click the link to review the publication )

Oral Oncol, 2014, 50(9):825-31

PubMed: 25017803 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1179-92

PubMed: 23913164 ( click the link to review the publication )

DNA Repair , 2016, 10.1016/j.dnarep.2016.06.001

PubMed: 27373144 ( click the link to review the publication )

DNA Repair , 2013, 12(12):1134-42

PubMed: 24210699 ( click the link to review the publication )

DNA Repair , 2012, 11(6):537-49

PubMed: 22542292 ( click the link to review the publication )

Cancer Sci, 2014, 105(2):202-10

PubMed: 24219164 ( click the link to review the publication )

Cancer Sci, 2012, 103(6):1045-50

PubMed: 22404155 ( click the link to review the publication )

J Cell Mol Med, 2014, 18(1):143-55

PubMed: 24238094 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1852(3):462-472

PubMed: 25483710 ( click the link to review the publication )
Biochim Biophys Acta, 2014, 1843(11):2662-2673

PubMed: 25072752 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1844(10):1765-72

PubMed: 25062913 ( click the link to review the publication )

J Trans Med, 2014, 12(1):184

PubMed: 24965603 ( click the link to review the publication )

J Biol Chem, 2013, 288(10):7086-95

PubMed: 23355489 ( click the link to review the publication )

J Biol Chem, 2012, 287(47):39824-33

PubMed: 21956491 ( click the link to review the publication )

J Biol Chem, 2012, 287(44):36777-91

PubMed: 22961983 ( click the link to review the publication )

J Biol Chem, 2012, 287(52):43720-9

PubMed: 23105099 ( click the link to review the publication )

Mol Pharmacol, 2014, 9(4):e95649

PubMed: 24748377 ( click the link to review the publication )

Mol Cell Biol, 2011, 31(12):2462-9

PubMed: 21482670 ( click the link to review the publication )

Cell Cycle, 2014, 12(11):1679-87

PubMed: 23656790 ( click the link to review the publication )

BMC Cancer, 2015, 15(1):1090

PubMed: 25777417 ( click the link to review the publication )

J Pharm Sci, 2014, 103(6):1913-20

PubMed: 24700236 ( click the link to review the publication )
PLoS One, 2014, 9(9):e108731

PubMed: 25264618 ( click the link to review the publication )

PLoS One, 2012, 7(6):e39956

PubMed: 22768182 ( click the link to review the publication )

PLoS One, 2011, 6(11):e27183

PubMed: 22073281 ( click the link to review the publication )

Dis Esophagus, 2015, 10.1111/dote.12299

PubMed: 25604309 ( click the link to review the publication )

J Cardiovasc Pharmacol, 2014, 10.1038/onc.2014.105

PubMed: 24769898 ( click the link to review the publication )

Medicine, 2014, 93(28):e294

PubMed: 25526472 ( click the link to review the publication )

Princeton University, 2015, 88435/dsp01br86b5821

PubMed: ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2012, 84(3):815-21

PubMed: 22417805 ( click the link to review the publication )

18 Customer Reviews

CYREN does not regulate repair of replication-induced DSBs. Representative images of chromosomes.

Nature, 2017, 549(7673):548-552. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

Clonogenic survival of cells expressing BARD1(WT)res or BARD1(AAE)res after treatment with olaparib or MMC. Data are means ± s.d., n = 3. EV, empty vector. P values were calculated using two-way ANOVA and multiple comparisons were corrected by the Bonferroni method. ** P < 0.01.

Nature, 2017, 550(7676):360-365. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.
a, IC50 levels of olaparib in EWS–FLI1 mutant cells (n = 17) versus breast cancers (n = 13) or pan-cancer (n = 147) dataset. b, Cell viability of IMR90 and Ewing sarcoma cells with increasing doses of olaparib. Mean ± s.d., n = 3 technical replicates, one-way ANOVA compared to IMR90 cells. c, Cell viability plot demonstrating the role of EWS–FLI1 in mediating exquisite sensitivity to olaparib in U2OS cells transfected with either the oncogene or empty vector; n = 3 transfection replicates.

Nature, 2018, 555(7696):387-391. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

Western blot analysis showing PARylated proteins in cells subject to the indicated PARP inhibitor treatments (5 μM Olaparib and 10 μM NU1025).

Cell, 2018, 172(3):439-453. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.
SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.
SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 24 (A) or 12 (B) hours, subjected to staining with propidium iodide (A) or FITC-Annexin V (B), and then analyzed by flow cytometry.

Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

Mechanism of FK866/olaparib synergy. FK866 exacerbates levels of gH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and gH2AX.

EMBO Mol Med 2012 4, 1087-1096. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.
Role of PARP and BER in the synergy between PTX and GMX in A549 cells. A) Cells were pre-treated +/- 1 uM olaparib (2h) then sequentially +/- 150nM PTX (24h) then +/- GMX 12nM (48h). Cells were harvested for (left) NAD+ quantification by LC-MS/MS (mean +/-SD of quadruplicates) or (right) viability by CellTiter-Glo (mean +/-SD of duplicates) B) PAR modification of proteins and γ-H2AX levels were measured in extracts treated as in A) by western blotting.

Cancer Res 2014 74(21), 5948-54. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

J Exp Clin Cancer Res 2013 32(1), 95. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.
(A) Representative confocal microscopy images of nuclear γ-H2AX (red) and DAPI (blue) staining in FKO1 cells 30 minutes following irradiation. Cells pre-treated for 24hr with 1μM NanoOlaparib, olaparib, or a vehicle control before irradiation.

Mol Cancer Ther, 2017, 16(7):1279-1289. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

MSH3-deficient cells are sensitive to olaparib, a PARP inhibitor, and the combination with oxaliplatin. A, clonogenic survival of HCT11635, G5 without doxycycline (DOX), and G5 cells with doxycycline, which were treated with 2 μM of oxaliplatin, 2 μM of olaparib, and the combination of these two drugs. B, clonogenic survival of HT29 cells, which were treated with 1 μM oxaliplatin, 2 μM olaparib, and the combination of these two drugs.

J Biol Chem 2011 286, 12157-12165. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.
Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.
Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

Nucl Med Commun 2011 32, 1046–1051 . Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

Olaparib inhibited cell proliferation, and CRC cells with high XRCC2 expression had higher olaparib sensitivity. The surviving fractions of SW480 cells treated with (A) 1 mM, (B) 10 mM, and (C) 50 mM olaparib were measured using CCK-8. (D) The relation between cell viability and olaparib concentration.

Medicine (Baltimore) 2014 93(28), e294. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.
in vivo suppression of PAR formation by the PARP inhibitor AZD2281 upon induction of DNA damage Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor AZD2281 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor. Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.

2010 Dr. David Schrmann from University of Base. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

Effect of AZD 2281 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

2010 Dr. Xiangbing Meng of University of Iowa. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

Features

A potent PARP inhibitor (currently in late stage clinical trials).

Targets

PARP2 ^[1] (Cell-free assay)	PARP1 ^[1] (Cell-free assay)
1 nM	5 nM

In vitro

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). ^[1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
KP3.33	NHTRSYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWW0JIQ>		M2TEW2lEPTB;NT63NFUhKM7:TTC=	M3e2cVE5PTV7NkGz
KP6.3	M1vONGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUmwSXZOPCCm		MXnJR\|UxRTFyLkSyPEDPxE1i	MWSxPFU2QTZzMx?=
KP7.7	M1j3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVG4T3JlPCCm		NIHlO5VKSzVyPUW3JI5OKA>?	MXyxPFU2QTZzMx?=
KB2P3.4	MmfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NH\nXWQ1KGR?		MVHJR\|UxRTF{NDDNJC=>	M33GflE5PTV7NkGz
KB2P1.21	NWjpN5FZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXW0JIQ>		MV7JR\|UxRTh7MEegcm0h	NXfoN4hROTh3NUm2NVM>
U373-MG	MVfDfZRwfG:6aXOgRZN{[Xl?	NYLmOJNWOSEQvF2g	NXrNPVZYOjRiaB?=		NWnVVmZ7UW6lcnXhd4V{KHKjZHnheIlwdiC\|ZX7zbZRqfmm2eR?=	M{HqTFE5QTV2N{Gy
T98G	M2PsUmN6fG:2b4jpZ{BCe3OjeR?=	M1jqd\|Eh\|ryPIB?=	Mk\UNlQhcA>?		M{KyVWlv[3KnYYPld{Bz[WSrYYTpc44he2Wwc3n0bZZqfHl?	NFTKN5IyQDl3NEexNi=>
U87-MG	Mn\OR5l1d3SxeHnjJGF{e2G7	NIHyc4EyKM7:TTC=	Ml\XNlQhcA>?		M4n6bGlv[3KnYYPld{Bz[WSrYYTpc44he2Wwc3n0bZZqfHl?	M3[1dVE5QTV2N{Gy
UVW	M1nHcmN6fG:2b4jpZ{BCe3OjeR?=	M4rqe\|UxOCCwTR?=	NYj5[ZlWOjRiaB?=		MkjpTY5kemWjc3XzJJJi\GmjdHnvckB{\W6\|aYTpeol1gQ>?	Mn60NVg6PTR5MUK=
HeLa	NXK0VJBSTnWwY4Tpc44hSXO\|YYm=	MnXhOVAxKG6P	NI\lfZQ1KGh?		NXXuS21{S2G3c3XzJIEhdW:mZYP0JIRmdGG7IHnuJJJmcm:rbnnu[{Bw\iC{YXTpZZRqd25vaX7keYNm\CCGTlGgZpJm[Wu\|	NGXreVUyQDl3NEexNi=>
HeLa	NW\BZ2lVTnWwY4Tpc44hSXO\|YYm=	M4jsUlEh\|ryPIB?=	MYSyOEBp		NF:wZWlGdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBUNXCqYYPlJIFzemW\|dB?=	NFHI[XoyQDl3NEexNi=>
T98G	NWOxOnlpTnWwY4Tpc44hSXO\|YYm=	NIPDbo0yKM7:TTC=	NVrTRpVpOjRiaB?=		Mk\PSY5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgV{1xcGG\|ZTDhdpJme3R?	M1;GNFE5QTV2N{Gy
L3	NVz4d45jS3m2b4TvfIlkKEG\|c3H5	NEDX[2U2KM7:TTC=	MWK5OkBp	M4OzR2ROW09?	NHvafWRUcWewaX\pZ4FvfGy7IHnubIljcXS\|IHPlcIwhe3W{dnn2ZYw>	NHLPRmQzODF{NES1PS=>
Granta-519	NFz0SW1EgXSxdH;4bYMhSXO\|YYm=	MUC1JO69VSB?	MU[5OkBp	NWTON5N1TE2VTx?=	Ml\DV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC\|dYL2bZZidA>?	NYDaXYhkOjBzMkS0OVk>
BT	NX23Wo1OS3m2b4TvfIlkKEG\|c3H5	M17OWFUh\|ryPIB?=	NF\abmI6PiCq	M1\4e2ROW09?	M4Xk[3NtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx?	MWmyNFEzPDR3OR?=
UPN2	MXfDfZRwfG:6aXOgRZN{[Xl?	NU\mTlRLPSEQvF2g	MXO5OkBp	M{HkbmROW09?	NFHUbIlUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu	NVjBSnlDOjBzMkS0OVk>
HBL-2	M{HQNGN6fG:2b4jpZ{BCe3OjeR?=	MlX0OUDPxE1i	NXfMcJBkQTZiaB?=	NI\QUGdFVVOR	MVnTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt	NHHvOIkzODF{NES1PS=>
JVM-2	NGqzWYNEgXSxdH;4bYMhSXO\|YYm=	MkP0OUDPxE1i	NW\LVnBOQTZiaB?=	M2fmbWROW09?	NH3HNFFUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu	Mn;XNlAyOjR2NUm=
Z138	M{T3NGN6fG:2b4jpZ{BCe3OjeR?=	Mn36OUDPxE1i	NHnJOVY6PiCq	MYPEUXNQ	MkniV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC\|dYL2bZZidA>?	NG\XTWkzODF{NES1PS=>
RWPE	MWTJcpZie2m4ZTDBd5NigQ>?	MYSyOUDPxE1?	MX60PEBp	MnXGSG1UVw>?	MVvTbYdvcW[rY3HueIx6KHKnZIXj[ZMhTVKJLXTybZZmdiClZXzsJIlvfmG\|aX;u	MXSyNVU4PTh4NR?=
VCaP	NV7RXHBYUW64YYPpeoUhSXO\|YYm=	NEPNWIMzPSEQvF2=	MYm0PEBp	M3LOZ2ROW09?	NWj2eJIzW2mpbnnmbYNidnSueTDy[YR2[2W\|IFXSS{1lemm4ZX6gZ4VtdCCrbo\hd4lwdg>?	MXyyNVU4PTh4NR?=
Mouse H2AX−/− ES Cells	MlLiR5l1d3SxeHnjJGF{e2G7	M{XSb\|IvPSEQvF2=	NVrSdW4yOjBiaB?=		M1n2dHNq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEB{fXK4aY\hcC=>	MUiyN\|M2PTR6OR?=
Mouse ATM−/− ES Cells	NWnQPYZ4S3m2b4TvfIlkKEG\|c3H5	MVqyMlUh\|ryP	M2jN[lIxKGh?		Moj4V4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJJN2en[rdnHs	MkPpNlM{PTV2OEm=
H1650	M{joWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3OyUFIxKM7:TR?=	MXuxOFQhcA>?		NGP3[21KSzVyPUG1MlQ4KM7:TR?=	NFrUZ28zOzJ\|OUiwPS=>
H1650PTEN+	NIfY[W5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjvNlAh\|ryP	NVvLb5g5OTR2IHi=		MUXJR\|UxRTVyLkizJO69VQ>?	NUP4WFdsOjN{M{m4NFk>
PC-9	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVeyNEDPxE1?	Ml:yNVQ1KGh?		NHfVTJNKSzVyPUWuPFgh\|ryP	MYOyN\|I{QThyOR?=
PC-9PTEN−	M1TQPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXWyNEDPxE1?	NXLVPZNWOTR2IHi=		NIfi[nFKSzVyPU[uOVIh\|ryP	Ml\ONlMzOzl6MEm=
MDA-MB-231	MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3f1VFUh\GG7		NULFXFlWUUN3ME22Mlkh\|ryP	MWWyN\|c3ODR7Nh?=
MDA-MB-468	M4PVfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NG\rOVI2KGSjeR?=		NFrVPI9KSzVyPUWuNEDPxE1?	MViyN\|c3ODR7Nh?=
BT20	NE\XZVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3;NVVUh\GG7		M33mTmlEPTB;Nz63JO69VQ>?	Mof1NlM4PjB2OU[=
HCC1143	M2fiS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVW1JIRigQ>?		NVvsWFF2UUN3ME2xNU4yKM7:TR?=	M{HPflI{PzZyNEm2
HCC1937	MlPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVzQb2ZtPSCmYYm=		MkfzTWM2OD1zMj62JO69VQ>?	M3TE[lI{PzZyNEm2
Hs578t	M4DBUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYe1JIRigQ>?		MUPJR\|UxRTVwNjFOwG0>	MnrzNlM4PjB2OU[=
Hs578t(si)	MoHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFvMb3M2KGSjeR?=		NWr0cI92UUN3ME23MlUh\|ryP	Mn;ONlM4PjB2OU[=
BT474	M17MV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHzrcmk2KGSjeR?=		MXPJR\|UxRTF7Lkig{txO	NX60S4NQOjN5NkC0PVY>
JIMT1	NHn1fm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFLxXY82KGSjeR?=		NEDQXXRKSzVyPUeuO{DPxE1?	NX\Wc3VuOjN5NkC0PVY>
SKBR3	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVi1JIRigQ>?		NWrKfVd7UUN3ME2xNU4yKM7:TR?=	MkfUNlM4PjB2OU[=
SUM159	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{HKNlUh\GG7		NUPkdlg3UUN3ME20MlIh\|ryP	MVmyN\|c3ODR7Nh?=
CAMA1	MljmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFTodZE2KGSjeR?=		NIfX[oVKSzVyPUG1Mlgh\|ryP	MVWyN\|c3ODR7Nh?=
MCF7	Ml\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4\Qe\|Uh\GG7		NYrIZZVWUUN3ME21Mlgh\|ryP	M3jaWVI{PzZyNEm2
T47D	NEGy[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUK1JIRigQ>?		Ml\kTWM2OD17Lk[g{txO	M3nCd\|I{PzZyNEm2
HCT116	M3fTVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnzNVAxKM7:TR?=	NUn5eJA3PDhiaB?=	NGS3RZdFVVOR	MXPJR\|UxRTJwNTFOwG0h	M1nCRlI1PTd5OUSx
SW1116	M3P3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\YOVRNOTByIN88US=>	MljtOFghcA>?	MoPrSG1UVw>?	NWLPT3JtUUN3ME2xNFAh\|ryP	NIf4VJIzPDV5N{m0NS=>
HT29	NEHERo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfHO4w2OTByIN88US=>	MVe0PEBp	NEXiZ2FFVVOR	NFzHNW5KSzVyPUG0Mlch\|ryP	Mkn3NlQ2Pzd7NEG=
LoVo	MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3Tob\|ExOCEQvF2=	Ml\SOFghcA>?	MmjuSG1UVw>?	NHnyeGtKSzVyPUGzMlQh\|ryP	NHS1TGMzPDV5N{m0NS=>
HCT-15	NWDmS3hJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGf2XIUyODBizszN	M3H5c\|Q5KGh?	MX3EUXNQ	M4TIeGlEPTB;MUCg{txO	Mor4NlQ2Pzd7NEG=
SW48	NEPkTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVz5Z3gzOTByIN88US=>	NWPhVHlSPDhiaB?=	M2Xkd2ROW09?	Mnv0TWM2OD17LkWg{txO	MmPiNlQ2Pzd7NEG=
C-1	M3XrT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HSTFExOCEQvF2=	M{DsUFQ5KGh?	NEDQdnBFVVOR	M2TCZWlEPTB;Nz62JO69VQ>?	MonrNlQ2Pzd7NEG=
RKO	MkjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVSxNFAh\|ryP	NUK1VZdiPDhiaB?=	M3juXGROW09?	NEXsXI9KSzVyPUWuPUDPxE1?	NUD5NGd7OjR3N{e5OFE>
HCT116	NGOydoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LqUVExOCEQvF2=	M2HRU\|Q5KGh?	NIjh[5JFVVOR	M{PpdHBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB?	M1XVWFI1PTd5OUSx
SW1116	M3rvSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\tVFYyODBizszN	M2DQOlQ5KGh?	Mn\DSG1UVw>?	NYDTb\|V7WG:2ZX70bYF1\XNiU16tN\|gh[3m2b4TvfIlkcXS7IB?=	MWCyOFU4Pzl2MR?=
HT29	M2X4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPMNVAxKM7:TR?=	M3;ZRlQ5KGh?	Ml\GSG1UVw>?	MmDsVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>?	M3LW[\|I1PTd5OUSx
LoVo	NEDNeIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHPNVAxKM7:TR?=	M1rUOVQ5KGh?	NXu3PIM5TE2VTx?=	NVOzPY1uWG:2ZX70bYF1\XNiU16tN\|gh[3m2b4TvfIlkcXS7IB?=	NGC0ToEzPDV5N{m0NS=>
SW48	M4HMN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnBT49kOTByIN88US=>	MXq0PEBp	MWrEUXNQ	Ml3UVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>?	NHqw[ngzPDV5N{m0NS=>
C-1	Mm\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{TqeFExOCEQvF2=	M4K4UVQ5KGh?	MkHSSG1UVw>?	M4DUdHBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB?	MWSyOFU4Pzl2MR?=
RKO	NX\qU\|BET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU[xNFAh\|ryP	MXm0PEBp	MVrEUXNQ	MnfpVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>?	MXiyOFU4Pzl2MR?=
HCT116	MVHGeY5kfGmxbjDBd5NigQ>?	M3TJc\|ExKG6P	MlfuNVIhcA>?	MlLMSG1UVw>?	NFy0cYNKdmO{ZXHz[ZMhTE6DIHTveYJt\S2\|dILhcoQh[nKnYXvzJIlv\HWlZXSgZpkhW05vM{i=	MYGyOFU4Pzl2MR?=
HT29	NYWyXYp[TnWwY4Tpc44hSXO\|YYm=	NYTNcmtqOTBibl2=	MmLtNVIhcA>?	NUDq[3BETE2VTx?=	M4XDRmlv[3KnYYPld{BFVkFiZH;1ZoxmNXO2cnHu[EBjemWja4OgbY5lfWOnZDDifUBUVi1\|OB?=	NWPQbpV5OjR3N{e5OFE>
TE-6	NITCXG1HfW6ldHnvckBCe3OjeR?=	NIjWR4k2KM7:TTC=	MorlNVIhcA>?	MXzEUXNQ	NXHPcGNjUW6mdXPld{BIOi:PIHHydoV{fA>?	NYnDSpZYOjR{MUmxOlQ>
TE-6	NGj3T4lHfW6ldHnvckBCe3OjeR?=	NWO2OGkyPSEQvF2g	MVyyOEBp	NYXtXIFwTE2VTx?=	MYfJcoNz\WG\|ZYOgbY4h\G:3YnzlJJN1emGwZDDidoVic3NiKFTTRpMq	NF;sbWYzPDJzOUG2OC=>
Hep3B	M{C0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjhb5A1OCEQvF2g	NIL0e3Y4OiCq	M2r5b2ROW09?	NX3UeY5bW3mwZYLnbZN1cWOjbHz5JIlvcGmkaYTzJINmdGxiZ4Lve5RpKHerdHigSGhOTVF?	NVLL[m4xOjVyN{K3OVI>
Huh7	MlrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\sOFAh\|ryPIB?=	NYLuVHZPPzJiaB?=	MXvEUXNQ	NUD6VWw1W3mwZYLnbZN1cWOjbHz5JIlvcGmkaYTzJINmdGxiZ4Lve5RpKHerdHigSGhOTVF?	NFi0fYszPTB5Mke1Ni=>
Hep3B	NX;ENJpHTnWwY4Tpc44hSXO\|YYm=	NWXkUXdzPDBizszNJC=>	NEi0[lMzPCCq	NYHkUWZVTE2VTx?=	Mm\jTY5lfWOnczDSU3MheHKxZIXjeIlwdiC5aYToJGRJVUWT	NGK1ZpkzPTB5Mke1Ni=>
Huh7	MkDDSpVv[3Srb36gRZN{[Xl?	M{LWelQxKM7:TTC=	NHfMdoYzPCCq	NWPxRWJWTE2VTx?=	NYP0ZY9yUW6mdXPld{BTV1NicILv[JVkfGmxbjD3bZRpKESKTVXR	NVLvOFJQOjVyN{K3OVI>
Hep3B	M{jFdGZ2dmO2aX;uJGF{e2G7	NIDQdYM1OCEQvF2g	NEXqUGUzPCCq	M1HSVWROW09?	M{Ow[Glv\HWlZYOgZ4VtdCCjdYTvdIhi\3lid3n0bEBFUE2HUR?=	NGHPVnAzPTB5Mke1Ni=>
Huh7	M2HGR2Z2dmO2aX;uJGF{e2G7	Mor0OFAh\|ryPIB?=	MlSzNlQhcA>?	NFe2S5JFVVOR	M3TTe2lv\HWlZYOgZ4VtdCCjdYTvdIhi\3lid3n0bEBFUE2HUR?=	M2PrVVI2ODd{N{Wy
SGC-7901	M{jlWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDnZ\|Y{OMLizszN	NX7TVXZvPDhiaB?=	NE\Hbo1FVVOR	MYnCcI9kcyCxeHHsbZBt[XSrbj3pcoR2[2WmIHPlcIwh\GWjdHi=	MljPNlU4PjdyN{[=
COLO-800	M3nUUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPqTlRjUUN3ME2wMlQ1OTZ2IN88US=>	NIPGU\|hUSU6JRWK=
EoL-1-	MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{TPOGlEPTB;MD61OlQ1PiEQvF2=	NEfGWXdUSU6JRWK=
NCI-H209	MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmizTWM2OD1yLkmxOVU3KM7:TR?=	NVLhPW9ZW0GQR1XS
ES1	M3HXTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTFwMUG0NFgh\|ryP	NH3Gdo9USU6JRWK=
NKM-1	MknxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTFwMkWzOFch\|ryP	M1HGUHNCVkeHUh?=
NTERA-S-cl-D1	NVjpdFZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\nTWM2OD1zLkOzN\|QyKM7:TR?=	M{n6bXNCVkeHUh?=
MHH-ES-1	M4HYUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnP2TWM2OD1zLk[yNFY4KM7:TR?=	MnHNV2FPT0WU
ES8	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTFwN{K0NVQh\|ryP	MnnEV2FPT0WU
NCI-H720	MlXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVrGZ2ZvUUN3ME2yMlIxPjl7IN88US=>	MlHRV2FPT0WU
EW-3	MlrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonyTWM2OD1{LkK3OVM1KM7:TR?=	NG\6[\|dUSU6JRWK=
D-566MG	M13zbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEOzXlJKSzVyPUKuOFQ2PjhizszN	M2jTbHNCVkeHUh?=
697	NFyzVZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PCPGlEPTB;Mj64OFE4OyEQvF2=	NYfnV5NGW0GQR1XS
ES5	NWr1PXlXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\YPXhKSzVyPUKuPFgyQDlizszN	MVrTRW5ITVJ?
COLO-684	M3XGZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\jU4JKSzVyPUOuOVE3QTZizszN	M2T0fXNCVkeHUh?=
ML-2	MkLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{[5SGlEPTB;Mz62NFA2QCEQvF2=	M3rndnNCVkeHUh?=
MC-IXC	MkHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvHRY1KSzVyPUOuOlM{QTNizszN	NFXXfYFUSU6JRWK=
DB	M2nhPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTNwNkW0OFgh\|ryP	NGS5e5hUSU6JRWK=
HCC2218	MoXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHFfWduUUN3ME2zMlc{OTB\|IN88US=>	NILmOIdUSU6JRWK=
NCI-H510A	NWDF[lZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1PHOGlEPTB;Mz64NlczPCEQvF2=	NID2OHdUSU6JRWK=
NCI-H526	MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\xTGlEPTB;Mz64Olk2QCEQvF2=	Mm\HV2FPT0WU
MV-4-11	M3vUO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4r6SWlEPTB;ND6xN\|M{PCEQvF2=	NUfpPY1YW0GQR1XS
PA-1	M{LlfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4PRRmlEPTB;ND6yOVI6KM7:TR?=	M1zKcXNCVkeHUh?=
EW-22	MoDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3kSHFTUUN3ME20MlM2QDZizszN	MlTiV2FPT0WU
KASUMI-1	MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjzTWM2OD12LkSwNVA6KM7:TR?=	MUPTRW5ITVJ?
LU-139	NXPCSlE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPHdo9KSzVyPUSuO\|U5OjlizszN	MYXTRW5ITVJ?
SBC-1	NXrVOnhzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjVTHJKSzVyPUSuPFA6ODhizszN	NG\zSmJUSU6JRWK=
H4	NVfKUlRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPQTXJKSzVyPUSuPFk1PDNizszN	NF3wVXlUSU6JRWK=
EW-11	NVrYV3I1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3znWWlEPTB;NT6wPFA4OiEQvF2=	M17ZWXNCVkeHUh?=
NBsusSR	NX7WSopzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIX6R3VKSzVyPUWuNVIxPTVizszN	MX7TRW5ITVJ?
RPMI-8226	NFjSVopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTVwMUWyOFQh\|ryP	NV:zXJNIW0GQR1XS
DEL	NGm1WmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUS5V\|RIUUN3ME21MlIxODB4IN88US=>	M{\6VHNCVkeHUh?=
ES4	M1;JNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLYV5dKSzVyPUWuOVE{QDlizszN	MX\TRW5ITVJ?
GCT	NUjy[XBtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWLMS5VmUUN3ME21MlU3QDV4IN88US=>	M1XtZ3NCVkeHUh?=
NCI-H1048	NFzsVnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYK1NJRYUUN3ME21Mlk4Ojd\|IN88US=>	NITUVodUSU6JRWK=
NCI-SNU-1	M{fNbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHHfZhKSzVyPU[uNFIzKM7:TR?=	Mn;HV2FPT0WU
ES7	NI\lOlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPNb252UUN3ME22MlA{PTd5IN88US=>	NUjlSIFZW0GQR1XS
SW982	M1\rWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVrP[G9FUUN3ME22MlA6OTN5IN88US=>	NYPhd4xFW0GQR1XS
L-363	MkfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvjVmxPUUN3ME22MlM{QTd2IN88US=>	Mli3V2FPT0WU
HT-1080	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXm4eZF4UUN3ME22MlQ6Pjh\|IN88US=>	NFPrXnVUSU6JRWK=
HAL-01	NWm5TnZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfRVHRiUUN3ME22MlUyODlizszN	MlXYV2FPT0WU
NB14	Mmq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1TiWmlEPTB;Nj62OFA{QSEQvF2=	NGnGT2FUSU6JRWK=
EW-13	M3XBOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFXPPJhKSzVyPU[uO\|c1OjRizszN	M3zHe3NCVkeHUh?=
NY	Mlq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;TTWM2OD14Lkm0OlA2KM7:TR?=	NGW5Z2FUSU6JRWK=
NCI-SNU-5	M3jkW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MorGTWM2OD15LkGwOFM{KM7:TR?=	NIHNe\|VUSU6JRWK=
MS-1	NYPvUXE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTdwMUe0PVQh\|ryP	NWnlOHU5W0GQR1XS
EW-16	NGPMUWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NESz[3pKSzVyPUeuN\|E5PjFizszN	NFXSU5JUSU6JRWK=
LU-65	NEfiN45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2XkSWlEPTB;Nz60PFQyPyEQvF2=	M1\2RXNCVkeHUh?=
HGC-27	NF\ONXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PnTWlEPTB;Nz63NlE4OyEQvF2=	NIDoSFRUSU6JRWK=
CTB-1	M2LJVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnrhTWM2OD15Lke2NVc2KM7:TR?=	NWDtd\|VKW0GQR1XS
5637	M1zlSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVHEVJlNUUN3ME23MlkzQDZizszN	NGDYSlRUSU6JRWK=
U251	NXLDZ2ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEfZTm1KSzVyPUeuPVQxOTZizszN	M1q1O3NCVkeHUh?=
HOS	M3PNWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn25TWM2OD16LkKzNFA4KM7:TR?=	MXLTRW5ITVJ?
DOHH-2	NEHzbWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH7HfoZKSzVyPUiuNlM2QCEQvF2=	M3H3U3NCVkeHUh?=
EW-1	MoTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVW3WnFQUUN3ME24MlMxODh6IN88US=>	M37PZnNCVkeHUh?=
BV-173	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPzNIU4UUN3ME24MlU2PTRizszN	NXmyeJVlW0GQR1XS
8-MG-BA	M1fMe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXmzPHRRUUN3ME24MlY5QTh6IN88US=>	NEnlS4pUSU6JRWK=
NB69	NWDaR3o{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGnTV3FKSzVyPUiuO\|A6OjFizszN	NIfXXIRUSU6JRWK=
NCI-H69	NFT1c3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTlwOUC5OlEh\|ryP	NYr3Rm0zW0GQR1XS
RS4-11	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLKTWM2OD1zMT6yNlA5KM7:TR?=	MYPTRW5ITVJ?
ONS-76	NF71PXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVK1T\|ltUUN3ME2xNU4zQTR5IN88US=>	NH3DWHFUSU6JRWK=
SF539	NUDEdllCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4LQfGlEPTB;MUGuOFg5QSEQvF2=	MV7TRW5ITVJ?
HuO-3N1	NWX0dVRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTFzLkW3PVYh\|ryP	MXjTRW5ITVJ?
NCI-H1651	M1HLdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NELUdotKSzVyPUGyMlMyOTVizszN	MmHUV2FPT0WU
KARPAS-45	MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorITWM2OD1zMj6zO\|Yh\|ryP	Mk\jV2FPT0WU
SK-NEP-1	NW\LNHhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3Gxd2lEPTB;MUKuOFYxQSEQvF2=	M2HNeXNCVkeHUh?=
LAMA-84	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTF\|LkGwPVUh\|ryP	MV\TRW5ITVJ?
NCI-H1155	MkPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NILwbXJKSzVyPUGzMlI5PTZizszN	Mnn5V2FPT0WU
CTV-1	NYrvbGNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTF\|LkS0OUDPxE1?	MlL2V2FPT0WU
QIMR-WIL	MmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGf0RYpKSzVyPUGzMlc5OTRizszN	M3qyeXNCVkeHUh?=
H9	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVz2eopCUUN3ME2xN{45PDd3IN88US=>	NG\IZ2pUSU6JRWK=
SK-MEL-1	M12xNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlTJTWM2OD1zMz65N\|Q4KM7:TR?=	MkTJV2FPT0WU
HD-MY-Z	M{fDXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXrwcpl5UUN3ME2xOE4xPjN5IN88US=>	NIHwW3FUSU6JRWK=
TI-73	NITueXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHVTWM2OD1zND6yN\|U3KM7:TR?=	MV3TRW5ITVJ?
JVM-3	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmrOTWM2OD1zNT61O\|E3KM7:TR?=	M2[yeXNCVkeHUh?=
D-247MG	MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\tTWM2OD1zNT61PVMh\|ryP	NIDzcZVUSU6JRWK=
VA-ES-BJ	M33q[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTF3Lk[wPVch\|ryP	M1L3UHNCVkeHUh?=
NOS-1	NFnsS\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWOxeJlGUUN3ME2xOU43PTJ{IN88US=>	M1q1WXNCVkeHUh?=
MOLT-4	Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVS2XIQ6UUN3ME2xOk44PTJizszN	MkDPV2FPT0WU
Mo-T	Mnr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVK3fGlNUUN3ME2xO{4xQDR7IN88US=>	NIPlcolUSU6JRWK=
NCI-H1770	NGCw[mVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHuOVdKSzVyPUG3MlE2PDNizszN	NELte25USU6JRWK=
COLO-320-HSR	MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTF5LkG4Nlch\|ryP	NGDMbodUSU6JRWK=
TE-12	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTDW5V3UUN3ME2xO{44ODV2IN88US=>	NF;iWpRUSU6JRWK=
NCI-H82	NWTSemwxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjXe3JCUUN3ME2xO{45PzJ6IN88US=>	NYroVphOW0GQR1XS
NEC8	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LCOmlEPTB;MUiuNVMyPiEQvF2=	Mo\wV2FPT0WU
HSC-3	Mn\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NESzUmdKSzVyPUG4Mlc1OTRizszN	NXztTYJ1W0GQR1XS
NCI-H1092	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTF6Lke1PVUh\|ryP	M1rvZnNCVkeHUh?=
NCI-H292	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn3lTWM2OD1zOT6wOFg6KM7:TR?=	MWTTRW5ITVJ?
L-428	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvid2ZKSzVyPUG5MlU2QSEQvF2=	NIHsTWlUSU6JRWK=
LU-134-A	MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTF7LkW3NkDPxE1?	Mn:4V2FPT0WU
GI-ME-N	NGDiXG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1S0V2lEPTB;MUmuOVc1PyEQvF2=	MUDTRW5ITVJ?
ALL-PO	NVnGOJpqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXrFUmR{UUN3ME2xPU42QTd{IN88US=>	NGrTbItUSU6JRWK=
D-283MED	M1rmSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PhXmlEPTB;MUmuPVE2KM7:TR?=	M4HCdXNCVkeHUh?=
D-423MG	MoTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jD[2lEPTB;MUmuPVk3PyEQvF2=	NX3yXYd7W0GQR1XS
CAKI-1	M1zOSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTJyLkKyNVkh\|ryP	NIOyTYtUSU6JRWK=
ETK-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4[1dWlEPTB;MkCuNlYyPSEQvF2=	MX\TRW5ITVJ?
G-402	MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknjTWM2OD1{MD61N\|M1KM7:TR?=	M1jROHNCVkeHUh?=
HL-60	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTJzLkG2NVMh\|ryP	Ml;PV2FPT0WU
A2058	M13PN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\qTWM2OD1{MT60OFc4KM7:TR?=	NGHy[5RUSU6JRWK=
CHP-212	M1S1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILNVZFKSzVyPUKxMlkxPTFizszN	M2jzSHNCVkeHUh?=
KY821	NFz3eJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1vReWlEPTB;MkGuPVc2KM7:TR?=	NEjlcZlUSU6JRWK=
TYK-nu	M1vq[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFX3ZZhKSzVyPUKyMlA3PTFizszN	M3nIWnNCVkeHUh?=
JVM-2	NWXabJVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mkf3TWM2OD1{Mj6yPVg{KM7:TR?=	NEToRZNUSU6JRWK=
KU812	M4nLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33FVmlEPTB;MkKuO\|MyOiEQvF2=	NVPIe4gzW0GQR1XS
MKN28	M{TDSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTJ{LkmwNVUh\|ryP	MkPhV2FPT0WU
ECC10	M2PEXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HPZmlEPTB;MkOuO\|QyKM7:TR?=	NXrESHMxW0GQR1XS
BHT-101	MorKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfuTWM2OD1{ND6wNFA5KM7:TR?=	M2m4bnNCVkeHUh?=
DU-4475	NXXkPYlGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXlTWM2OD1{ND6zN\|M4KM7:TR?=	NXvIdoZ7W0GQR1XS
769-P	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW[zUGxPUUN3ME2yOE45PDZ4IN88US=>	M2HOOXNCVkeHUh?=
HEC-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLiTWM2OD1{NT60OFUh\|ryP	Moi4V2FPT0WU
MOLT-13	M1GwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTJ3LkWzN\|Eh\|ryP	NVu0XlA2W0GQR1XS
8505C	MkXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTJ4LkS5O\|ch\|ryP	MmDGV2FPT0WU
GB-1	M4HNNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvJZYNKSzVyPUK2MlcyPzZizszN	M{C2UHNCVkeHUh?=
SF126	NYLzNXdCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVLTR\|duUUN3ME2yOk44PjR6IN88US=>	NELzWYFUSU6JRWK=
A4-Fuk	NIjRNpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGr4RmpKSzVyPUK3MlEzPzFizszN	M122ZXNCVkeHUh?=
OVCAR-8	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PjTmlEPTB;MkeuNVU{QSEQvF2=	M1\kUnNCVkeHUh?=
NCI-H1304	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LnTWlEPTB;MkeuOVQh\|ryP	MWTTRW5ITVJ?
GR-ST	MmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlT0TWM2OD1{OD6wOFch\|ryP	MXfTRW5ITVJ?
G-401	MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTJ6LkWwPVYh\|ryP	M{LGTHNCVkeHUh?=
LXF-289	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\3TI5KSzVyPUK4MlU3PTFizszN	MU\TRW5ITVJ?
DBTRG-05MG	MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\lW2lEPTB;MkiuPVIxPCEQvF2=	M3v1bnNCVkeHUh?=
YKG-1	M4rydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTJ7Lki2PEDPxE1?	MVLTRW5ITVJ?
GAMG	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvDNFFKSzVyPUK5Mlk6OyEQvF2=	NX[3OIdNW0GQR1XS
HCT-116	NEi0WW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDlTWM2OD1\|MD6wOVQ5KM7:TR?=	NUjtWWtXW0GQR1XS
S-117	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLWSZFKSzVyPUOxMlIzPTdizszN	M3PKZ3NCVkeHUh?=
NCI-H1693	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3z0V2lEPTB;M{OuOlU1OiEQvF2=	MUfTRW5ITVJ?
A427	NIfYcVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DpUGlEPTB;M{OuPVk4PiEQvF2=	NUHN[HNiW0GQR1XS
HT-29	NFHiNpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDHTWM2OD1\|ND62NFMzKM7:TR?=	MUXTRW5ITVJ?
P12-ICHIKAWA	M2LPOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPtNpVKSzVyPUO0Mlc1QTFizszN	MmL1V2FPT0WU
CAL-51	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDxW\|ZFUUN3ME2zOU4xPzB7IN88US=>	MYHTRW5ITVJ?
Ramos-2G6-4C10	NUnCU25bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlu5TWM2OD1\|NT6yOFI2KM7:TR?=	MVTTRW5ITVJ?
SCH	NVHoN3BnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEL4VINKSzVyPUO2MlQyPzRizszN	NVn3O4p6W0GQR1XS
SK-MEL-24	MnvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTN4LkmwOFQh\|ryP	NIPOPGJUSU6JRWK=
SW1573	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTN6LkeyNVYh\|ryP	M4jRNHNCVkeHUh?=
BALL-1	NVLOeGxuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jDeWlEPTB;M{muNlEzQSEQvF2=	M1Xie3NCVkeHUh?=
BE-13	M4LQTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn6xTWM2OD1\|OT6zNlkh\|ryP	NIGyfmdUSU6JRWK=
GI-1	NYPDd5pST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmP4TWM2OD1\|OT64OlQ4KM7:TR?=	M2LueHNCVkeHUh?=
GOTO	MkTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTN7LkmxN\|kh\|ryP	NVTzbZo1W0GQR1XS
A673	M4O4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrUWGhKSzVyPUSxMlA{PDNizszN	MYTTRW5ITVJ?
KG-1	NIThe\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHSWVVKSzVyPUSzMlM6PCEQvF2=	MXnTRW5ITVJ?
GP5d	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDITWM2OD12ND6wOlY3KM7:TR?=	M1P4THNCVkeHUh?=
MFM-223	NUjRdIc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTR2LkGyNlgh\|ryP	M2jzcnNCVkeHUh?=
OAW-42	NYHm[VVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGWz[lNKSzVyPUS0MlI3PDNizszN	MlnnV2FPT0WU
C8166	NXG2fpkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTR3LkC4NlIh\|ryP	NF7MSZlUSU6JRWK=
LU-99A	Mo[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jmcGlEPTB;NE[uNVMzOiEQvF2=	MWLTRW5ITVJ?
NCI-H23	M2OzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTR4LkG3PFUh\|ryP	M{\EWnNCVkeHUh?=
HO-1-N-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;GWndOUUN3ME20O{4xQTl6IN88US=>	Ml3qV2FPT0WU
A3-KAW	M2f4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3lTWM2OD12Nz6xNFA4KM7:TR?=	Mn\zV2FPT0WU
CGTH-W-1	M4XEUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTR5LkWwOlkh\|ryP	NUS5O4VRW0GQR1XS
DJM-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLmOWhKSzVyPUS3MlU1OTNizszN	MlO0V2FPT0WU
A101D	NWHodox2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTR5Lk[zOVch\|ryP	NUXtXHk3W0GQR1XS
BB30-HNC	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYHHW2JmUUN3ME20PE4{ODd{IN88US=>	MlTJV2FPT0WU
T98G	MofwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HufGlEPTB;NEiuOFY{OyEQvF2=	NILEXXRUSU6JRWK=
NCI-H1573	NWnPcY5yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\4TWM2OD12OT60OFYzKM7:TR?=	MWHTRW5ITVJ?
MEG-01	NXX6UFVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTR7Lke0NVEh\|ryP	NX;M[IJPW0GQR1XS
WM-115	M1frSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHwTWM2OD12OT65NlIzKM7:TR?=	NIXyV3FUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western Blot	DR5/CHOP; PubMed: 25531448 PLoS One (A) U87 GBM cells were treated with Olaparib (10 µM) for the indicated time points, subjected to immunoblotting and analyzed for the expression of DR5. B-D) U87 (B), U373 (C) and LN229 GBM cells (D) were treated with increasing concentrations of Olaparib (µM) for 7 hours, subjected to immunoblotting and analyzed for the expression of CHOP and DR5. E–F) MDA-MB-468 (E) and MDA-MB-436 (F) were treated with increasing concentrations (µM) of Olaparib for 7 hours, harvested for immunoblotting and analyzed for the expression of DR5. γH2AX/H2AX; PubMed: 22933245 EMBO Mol Med FK866 exacerbates levels of γH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and γH2AX. pATM; PubMed: 27686740 Cell cycle (C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. 53BP1; PubMed: 27686740 Cell cycle (C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. NF-kB; PubMed: 27686740 Cell cycle (C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. pS6/S6; PubMed: 24831086 Oncotarget HCC1937 cells (BRCA1-inactive) were treated with 10 nM olaparib with indicated times. Whole-cell lysates were prepared and analyzed by Western blotting with the indicated antibodies.	25531448 22933245 27686740 24831086
Immunofluorescence	DNA damage; PubMed: 27686740 Cell Cycle (A) A comet assay and (B) γH2AX immunofluorescence assay were performed 72 h after olaparib treatment to identify DNA damage. A relatively higher level of DNA damage was observed in HN9-cisR cells; however, olaparib also induced slight DNA damage in olaparib-resistant HN4-cisR cells. Magnification: × 100 (comet assay); × 400 (γH2AX). γH2AX; PubMed: 28069876 Mol Cancer Ther Representative images of immunofluorescence (IF) staining for γH2AX in 22RV1 cells treated with of BI2536 (5 nM), Olaparib (10 µM) or both for 24 h. 22RV1 cells (1 × 105) were plated in 6-well plates on day 0 and then treated with BI2536, Olaparib or both for 24 h.	27686740 28069876
Growth inhibition assay	Cell viability ; PubMed: 25531448 PLoS One A-D): U87 (A), U373 (B), LN229 (C) and MDA-MB-468 (D) cells were treated with suboptimal dosages of TRAIL (A: 100 ng/ml, B: 25 ng/ml, C: TRAIL 200 ng/ml, D: 10 ng/ml), Olaparib (A–C: 10 µM, D: 5 µM) or the combination of both reagents for 48 hours. Thereafter, MTT assays were performed to determine cellular viability.	25531448
ELISA	IL-8; PubMed: 28456021 Virology ELISA measuring PAR levels in Akata-EBV cells. Cells were treated with 2.5 μM olaparib for 24 h to inhibit PARP activity. Data are shown as pg of PAR per μg of protein. GLP-1; PubMed: 29392078 Aging Dis Olaparib enhances promotes GLP-1 secretion in NCI-H716 cells Cells were stimulated for 30 minutes with or without 16 mM glucose. GLP-1 was measured by ELISA. Bars represent the mean of three independent experiments normalized to the control. Error bars indicate standard deviation. Statistical analyses were performed by two-tailed Student’s t-test and significance is denoted by asterisks where *P<0.05.	28456021 29392078

In vivo

Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. ^[1] Olaparib shows great response to Brca1^-/-;p53^-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad^-/-;p53^-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. ^[3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. ^[4]

Protocol

Kinase Assay: ^[1]	+ Expand FlashPlate assay (96-well screening assay): To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl₂,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD⁺ final assay concentration, and 0.075 μCi ³H-NAD⁺ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
Cell Research: ^[1]	+ Expand Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D Concentrations: 1-300 nM Incubation Time: 7-14 days Method: The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50. (Only for Reference)
Animal Research: ^[3]	+ Expand Animal Models: Brca1^-/-;p53^-/- mammary tumors are generated in K14cre;Brca1^F/F;p53^F/F mice. Formulation: 50 mg/mL stocks in DMSO with 10% 2-hydroxyl-propyl-β-cyclodextrine/PBS Dosages: 50 mg/kg Administration: Administered via i.p. injection at 10 μL/g of body weight (Only for Reference)

References

[4] Weston VJ, et al, Blood, 2010, 116(22), 4578-4587.

+ Expand

Solubility (25°C)

In vitro	DMSO	86 mg/mL warmed (197.94 mM)
	Water	0.002 mg/mL (0.0 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Olaparib (AZD2281, Ku-0059436) SDF

Molecular Weight	434.46
Formula	C₂₄H₂₃FN₄O₃
CAS No.	763113-22-0
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03561870	Not yet recruiting	Recurrent IDH\|Mutant High Grade Glioma	Hospices Civils de Lyon	December 1 2019	Phase 2
NCT03561870	Not yet recruiting	Recurrent IDH\|Mutant High Grade Glioma	Hospices Civils de Lyon	December 1 2019	Phase 2
NCT03741426	Not yet recruiting	Renal Cell Cancer	CCTU- Cancer Theme\|University of Cambridge\|AstraZeneca\|Cancer Research UK\|Cambridge University Hospitals NHS Foundation Trust	July 25 2019	Phase 2
NCT03741426	Not yet recruiting	Renal Cell Cancer	CCTU- Cancer Theme\|University of Cambridge\|AstraZeneca\|Cancer Research UK\|Cambridge University Hospitals NHS Foundation Trust	July 25 2019	Phase 2
NCT03880019	Not yet recruiting	Stage III Uterine Corpus Leiomyosarcoma AJCC v8\|Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8\|Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8\|Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8\|Stage IV Uterine Corpus Leiomyosarcoma AJCC v8\|Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8\|Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8	National Cancer Institute (NCI)	June 7 2019	Phase 2
NCT03842228	Not yet recruiting	Advanced Malignant Solid Neoplasm\|ARID1A Gene Mutation\|ATM Gene Mutation\|ATRX Gene Mutation\|BARD1 Gene Mutation\|BRCA1 Gene Mutation\|BRCA2 Gene Mutation\|BRIP1 Gene Mutation\|CDK12 Gene Mutation\|CHEK1 Gene Mutation\|CHEK2 Gene Mutation\|FANCA Gene Mutation\|FANCL Gene Mutation\|Metastatic Malignant Solid Neoplasm\|MRE11 Gene Mutation\|MSH2 Gene Mutation\|PALB2 Gene Mutation\|PARP1 Gene Mutation\|PIK3CA Gene Mutation\|POLD1 Gene Mutation\|PPP2R2A Gene Mutation\|PTEN Gene Mutation\|RAD51B Gene Mutation\|RAD51C Gene Mutation\|RAD51D Gene Mutation\|RAD54L Gene Mutation\|Unresectable Malignant Solid Neoplasm\|XRCC2 Gene Mutation	National Cancer Institute (NCI)	June 10 2019	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to prepare the solution of the compound (S1060) for in vivo study?
Answer:
We recommend the following formulation: 4% DMSO+30% PEG300+ 66%H2O. It is a clear solution and can be used for IP injection.
Question 2:
I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?
Answer:
For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.
Question 3:
How long can the chemical compound be stable in DMEM at 4 °C?
Answer:
The compound is stable in DMEM at 4 degree for one week.

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Selective PARP Inhibitors

AG-14361 : PARP1-selective, K_i<5 nM.
Selective PARP Inhibitors

UPF 1069 : PARP2-selective, IC50=0.3 μM.
Most Potent PARP Inhibitor

MK-4827 (Niraparib) : PARP1, IC50=3.8 nM; PARP2, IC50=2.1 nM.
PARP Inhibitor in Clinical Trial

Iniparib (BSI-201) : Phase III for solid tumors.
Newest PARP Inhibitor

BMN 673 : Novel PARP inhibitor with IC50 of 0.58 nM. Also a potent inhibitor of PARP-2, but does not inhibit PARG and highly sensitive to PTEN mutation.

Related PARP Products5

G007-LK ^New

G007-LK is a potent and selective tankyrase inhibitor with IC50 of 46 nM and 25 nM for TNKS1/2, respectively.
NU1025 ^New

NU1025 is a potent PARP inhibitor with IC50 of 400 nM.
SCR7 ^New

SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.
Veliparib (ABT-888)

Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with K_i of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.

Features:Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
Rucaparib (AG-014699,PF-01367338) phosphate

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with K_i of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

Features:The first PARP inhibitor used in clinical trials combined with temozolomide.
Talazoparib (BMN 673)

Talazoparib (BMN 673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.

Features:Most potent and selective PARPi reported thus far.
Iniparib (BSI-201)

Iniparib (BSI-201) is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC). Phase 3.
PJ34 HCl

PJ34 HCl is the hydrochloride salt of PJ34, which is a PARP inhibitor with EC50 of 20 nM and is equally potent to PARP1/2.

Features:Water-soluble PARP1/2 inhibitor with >10,000-fold potentcy vs. 3-aminobenzamide (prototypical PARP inhibitor). Potential uses in cardiovascular diseases (stroke, cerebral ischemia, & myocardial ischemia).
AG-14361

AG14361 is a potent inhibitor of PARP1 with K_i of <5 nM in a cell-free assay. It is at least 1000-fold more potent than the benzamides.

Features:The 1st high-potency PARP-1 inhibitor with the specificity & in vivo activity to enhance chemotherapy and radiation therapy of human cancers.
A-966492

A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with K_i of 1 nM and 1.5 nM, respectively.

Features:A promising, structurally diverse benzimidazole analogue that is being further characterized preclinically.

Choose Your Country or Region

By Signaling Pathways

By product type

Olaparib (AZD2281, Ku-0059436)

Cited by 92 Publications

18 Customer Reviews

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Olaparib (AZD2281, Ku-0059436) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products5

Choose Your Country or Region

By Signaling Pathways

By product type

Olaparib (AZD2281, Ku-0059436)

Cited by 92 Publications

18 Customer Reviews

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Olaparib (AZD2281, Ku-0059436) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products5

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)